Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 474841 - 474860 out of 505060 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Switzerland | (L01EA02) dasatinib (adm: O) | Dasatinib Accord, Filmtabl 50 mg, Blist 60 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive | AccordHealthcareAG |
| Switzerland | (L01EA02) dasatinib (adm: O) | Dasatinib Accord, Filmtabl 70 mg, Blist 60 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive | AccordHealthcareAG |
| Switzerland | (L01EA03) nilotinib (adm: O) | Nilotinib Spirig HC, Kaps 150 mg, Blist 112 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
n/a | SpirigHealthCareAG |
| Switzerland | (L01EA03) nilotinib (adm: O) | Nilotinib Spirig HC, Kaps 200 mg, Blist 112 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
n/a | SpirigHealthCareAG |
| Switzerland | (L01EA03) nilotinib (adm: O) | Nilotinib Spirig HC, Kaps 200 mg, Blist 28 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
n/a | SpirigHealthCareAG |
| Switzerland | (L01EA03) nilotinib (adm: O) | Tasigna, Kaps 150 mg, 112 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaSchweizAG |
| Switzerland | (L01EA03) nilotinib (adm: O) | Tasigna, Kaps 200 mg, 112 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaSchweizAG |
| Switzerland | (L01EA03) nilotinib (adm: O) | Tasigna, Kaps 200 mg, 28 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | NovartisPharmaSchweizAG |
| Switzerland | (L01EH01) lapatinib (adm: O) | Tyverb, Tabs 250 mg, Ds 140 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | NovartisPharmaSchweizAG |
| Switzerland | (L01EH01) lapatinib (adm: O) | Tyverb, Tabs 250 mg, Ds 70 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Breast Neoplasms | NovartisPharmaSchweizAG |
| Switzerland | (L01FC02) isatuximab | Sarclisa, Inf Konz 100 mg/5ml, Durchstf 5 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | Sanofi-Aventis(Suisse)SA |
| Switzerland | (L01FC02) isatuximab | Sarclisa, Inf Konz 500 mg/25ml, Durchstf 25 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Multiple Myeloma | Sanofi-Aventis(Suisse)SA |
| Switzerland | (L01FF01) nivolumab | Opdivo, Inf Konz 100 mg/10 ml, Durchstf 10 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbSA |
| Switzerland | (L01FF01) nivolumab | Opdivo, Inf Konz 240 mg/24 ml, Durchstf 24 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbSA |
| Switzerland | (L01FF01) nivolumab | Opdivo, Inf Konz 40 mg/4 ml, Durchstf 4 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms | Bristol-MyersSquibbSA |
| Switzerland | (L01FF04) avelumab | Bavencio, Inf Konz 200 mg/10 ml, 4 Durchstf 10 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Neuroendocrine Tumors | Merck(Schweiz)AG |
| Switzerland | (L01FF04) avelumab | Bavencio, Inf Konz 200 mg/10 ml, Durchstf 10 ml | n/a | Retail price with vat |
$0-0 |
$0-0 |
Neuroendocrine Tumors | Merck(Schweiz)AG |
| Switzerland | (L01FF09) tislelizumab | Tevimbra, Inf Konz 100 mg/10ml, Durchstf 1 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
Esophageal Squamous Cell Carcinoma | BeOneMedicinesIGmbH |
| Switzerland | (L01FG01) bevacizumab | Bevacizumab-Teva, Inf Konz 100 mg/4 ml, Durchstf 1 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
n/a | TevaPharmaAG |
| Switzerland | (L01FG01) bevacizumab | Bevacizumab-Teva, Inf Konz 400 mg/16 ml, Durchstf 1 Stk | n/a | Retail price with vat |
$0-0 |
$0-0 |
n/a | TevaPharmaAG |
Pages
